FIELD: medicine, virology, oncology. SUBSTANCE: method involves an administration of new prepared interferons of so called "coordinated interferons" - INF-con, in part, INF-con-1, INF-con-2 and INF-con-3 at doses (2-30) x 106 U per a patient. Invention proposes also drugs for this treatment that involve the corresponding pharmaceutically acceptable vehicles and additional agents - carriers, preserving and solubilizing agents. Preparation can contain additionally a granulocyte colony-stimulating factor at the dose 5-6 mcg/kg/day. Method is used for treatment of patients with Kaposi's sarcoma and viral hepatitis C. EFFECT: enhanced effectiveness of method, decreased adverse effect of interferon therapy. 12 cl, 5 tbl, 8 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATMENT OF FUNGUS-LIKE MYCOSIS | 2003 |
|
RU2234921C1 |
THERAPEUTIC USE OF KERATINOCYTE GROWTH FACTOR | 1994 |
|
RU2146148C1 |
COMPOSITION FOR TREATING AIDS | 1988 |
|
RU2016572C1 |
METHOD OF TREATING CHRONIC VIRAL HEPATITIS C WITH MEDICATIONS IN LIPOSOMAL FORM | 2011 |
|
RU2475263C1 |
METHOD FOR TREATMENT OF CHRONIC HEPATITIS | 2005 |
|
RU2286792C1 |
N-ACETYLCYSTEINE-CONTAINING COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS AND TOXICITY OF DRUGS | 2002 |
|
RU2291689C2 |
USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
METHOD OF CHRONIC VIRUS HEPATITIS TREATMENT | 2008 |
|
RU2369403C1 |
FUSED PROTEIN ELICITING BIOLOGICAL ACTIVITY OF INTERFERON-ALPHA, DIMERIC FUSED PROTEIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, DNA MOLECULE (VARIANTS) AND METHOD FOR TARGETING INTERFERON-ALPHA INTO LIVER TISSUE | 2000 |
|
RU2262510C9 |
COMPOSITIONS AND METHODS OF TREATMENT OF LIVER CANCER | 2018 |
|
RU2802962C2 |
Authors
Dates
1999-03-27—Published
1993-04-14—Filed